Cargando…

Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy

INTRODUCTION: Infection with HIV subtype A has been associated with poorer neurocognitive outcomes compared to HIV subtype D in Ugandan children not eligible for antiretroviral therapy (ART). In this study, we sought to determine whether subtype‐specific differences are also observed among children...

Descripción completa

Detalles Bibliográficos
Autores principales: Bangirana, Paul, Ruel, Theodore D, Boivin, Michael J, Pillai, Satish K, Giron, Leila B, Sikorskii, Alla, Banik, Asish, Achan, Jane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810341/
https://www.ncbi.nlm.nih.gov/pubmed/29052340
http://dx.doi.org/10.1002/jia2.25015
_version_ 1783299740564193280
author Bangirana, Paul
Ruel, Theodore D
Boivin, Michael J
Pillai, Satish K
Giron, Leila B
Sikorskii, Alla
Banik, Asish
Achan, Jane
author_facet Bangirana, Paul
Ruel, Theodore D
Boivin, Michael J
Pillai, Satish K
Giron, Leila B
Sikorskii, Alla
Banik, Asish
Achan, Jane
author_sort Bangirana, Paul
collection PubMed
description INTRODUCTION: Infection with HIV subtype A has been associated with poorer neurocognitive outcomes compared to HIV subtype D in Ugandan children not eligible for antiretroviral therapy (ART). In this study, we sought to determine whether subtype‐specific differences are also observed among children receiving ART. MATERIALS AND METHODS: Children were recruited from a clinical trial in which they were randomized to receive either lopinavir (LPV)‐ or non‐nucleoside reverse transcriptase inhibitor (NNRTI)‐ based ART (NCT00978068). Age at initiation of ART ranged from six months to six years. HIV subtype was determined by PCR amplification and population sequencing of the pol region derived from peripheral blood mononuclear cell DNA, followed by application of the REGA and Recombinant Identification Programme algorithms. General cognition was assessed using the Kaufman Assessment Battery for Children (Second Edition), attention using the Test of Variables of Attention, and motor skills using the Bruininks‐Oseretsky Test of Motor Proficiency (Second Edition). Home environment was assessed using the Home Observation for the Measurement of the Environment (HOME). Age‐adjusted test z‐scores were entered into a regression model that adjusted for sex, socio‐economic status score, HOME score, years of schooling, and ART treatment type. RESULTS: One hundred and five children were tested; median (interquartile range) age was 7.05 years (6.30 to 8.44), CD4 count was 867.7 cells/mm(3) (416.0 to 1203.5), and duration on ART was 4.03 years (3.55 to 4.23). Seventy‐eight children had HIV subtype A and 27 had subtype D; the groups had comparable home and socio‐economic status, except that there were more males among children infected with subtype A than D (64.7% vs. 35.3%, p = 0.02). There were no differences between the subtypes in general cognition (estimated mean difference: 0.20; 95% CI: −0.11 to 0.50); p = 0.21), attention (−0.18, 95% CI: −0.60 to 0.24, p = 0.41) and motor skills (1.60, 95% CI: −0.84 to 4.04, p = 0.20). CONCLUSIONS: Our results imply that ART may diminish the neurocognitive disadvantage seen in treatment‐naïve HIV‐infected children with subtype A.
format Online
Article
Text
id pubmed-5810341
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58103412018-02-14 Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy Bangirana, Paul Ruel, Theodore D Boivin, Michael J Pillai, Satish K Giron, Leila B Sikorskii, Alla Banik, Asish Achan, Jane J Int AIDS Soc Short Reports INTRODUCTION: Infection with HIV subtype A has been associated with poorer neurocognitive outcomes compared to HIV subtype D in Ugandan children not eligible for antiretroviral therapy (ART). In this study, we sought to determine whether subtype‐specific differences are also observed among children receiving ART. MATERIALS AND METHODS: Children were recruited from a clinical trial in which they were randomized to receive either lopinavir (LPV)‐ or non‐nucleoside reverse transcriptase inhibitor (NNRTI)‐ based ART (NCT00978068). Age at initiation of ART ranged from six months to six years. HIV subtype was determined by PCR amplification and population sequencing of the pol region derived from peripheral blood mononuclear cell DNA, followed by application of the REGA and Recombinant Identification Programme algorithms. General cognition was assessed using the Kaufman Assessment Battery for Children (Second Edition), attention using the Test of Variables of Attention, and motor skills using the Bruininks‐Oseretsky Test of Motor Proficiency (Second Edition). Home environment was assessed using the Home Observation for the Measurement of the Environment (HOME). Age‐adjusted test z‐scores were entered into a regression model that adjusted for sex, socio‐economic status score, HOME score, years of schooling, and ART treatment type. RESULTS: One hundred and five children were tested; median (interquartile range) age was 7.05 years (6.30 to 8.44), CD4 count was 867.7 cells/mm(3) (416.0 to 1203.5), and duration on ART was 4.03 years (3.55 to 4.23). Seventy‐eight children had HIV subtype A and 27 had subtype D; the groups had comparable home and socio‐economic status, except that there were more males among children infected with subtype A than D (64.7% vs. 35.3%, p = 0.02). There were no differences between the subtypes in general cognition (estimated mean difference: 0.20; 95% CI: −0.11 to 0.50); p = 0.21), attention (−0.18, 95% CI: −0.60 to 0.24, p = 0.41) and motor skills (1.60, 95% CI: −0.84 to 4.04, p = 0.20). CONCLUSIONS: Our results imply that ART may diminish the neurocognitive disadvantage seen in treatment‐naïve HIV‐infected children with subtype A. John Wiley and Sons Inc. 2017-10-20 /pmc/articles/PMC5810341/ /pubmed/29052340 http://dx.doi.org/10.1002/jia2.25015 Text en © 2017 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Short Reports
Bangirana, Paul
Ruel, Theodore D
Boivin, Michael J
Pillai, Satish K
Giron, Leila B
Sikorskii, Alla
Banik, Asish
Achan, Jane
Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy
title Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy
title_full Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy
title_fullStr Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy
title_full_unstemmed Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy
title_short Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy
title_sort absence of neurocognitive disadvantage associated with paediatric hiv subtype a infection in children on antiretroviral therapy
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810341/
https://www.ncbi.nlm.nih.gov/pubmed/29052340
http://dx.doi.org/10.1002/jia2.25015
work_keys_str_mv AT bangiranapaul absenceofneurocognitivedisadvantageassociatedwithpaediatrichivsubtypeainfectioninchildrenonantiretroviraltherapy
AT rueltheodored absenceofneurocognitivedisadvantageassociatedwithpaediatrichivsubtypeainfectioninchildrenonantiretroviraltherapy
AT boivinmichaelj absenceofneurocognitivedisadvantageassociatedwithpaediatrichivsubtypeainfectioninchildrenonantiretroviraltherapy
AT pillaisatishk absenceofneurocognitivedisadvantageassociatedwithpaediatrichivsubtypeainfectioninchildrenonantiretroviraltherapy
AT gironleilab absenceofneurocognitivedisadvantageassociatedwithpaediatrichivsubtypeainfectioninchildrenonantiretroviraltherapy
AT sikorskiialla absenceofneurocognitivedisadvantageassociatedwithpaediatrichivsubtypeainfectioninchildrenonantiretroviraltherapy
AT banikasish absenceofneurocognitivedisadvantageassociatedwithpaediatrichivsubtypeainfectioninchildrenonantiretroviraltherapy
AT achanjane absenceofneurocognitivedisadvantageassociatedwithpaediatrichivsubtypeainfectioninchildrenonantiretroviraltherapy